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GENOME-WIDE PROFILING OF 5-FORMYLCYTOSINE AND 5-
CARBOXYLCYTOSINE IN MELANOMA 
KIMBERLIE ANN MARQUES RABIDOU 
ABSTRACT 
Malignant melanoma, which comprises only 2% of skin cancers cases, but is the 
most lethal form of skin cancer. With the prevalence of melanoma continuing to rise, 
there is a greater need to elucidate the mechanisms underlying disease initiation and 
progression. Because mutations in melanoma-associated genes account for only 10% of 
cases, epigenome-altering environmental factors must have a role in pathogenesis. DNA 
methylation and demethylation are key epigenetics processes which govern cell 
differentiation and development. 5-methylcytosine (5mC) is a key epigenetic mark, 
which undergoes oxidation to 5-hydroxymethylcytosine (5hmC), 5formylcytosine (5fC) 
and 5carboxycytosine (5caC) during demethylation. In melanoma, it has been established 
that the loss of 5hmC is a cancer hallmark and is associated with poor prognostic 
outcome. The roles of 5fC/5caC, however, are not known. Here, I aimed to investigate 
the role of 5fC/5caC in melanoma and its contribution to disease development. Using 
methylase-assisted bisulfite sequencing, I have mapped the genome-wide distribution of 
5fC/5caC at base pair resolution in two melanoma cell lines, A2058 and Mel Juso. In 
both cell lines, this modification is enriched at distal regulatory elements. Comparisons of 
differentially methylated sites and regions between the cell lines revealed that the 
products of 5fC/5caC enriched genes participate in cell adhesion and cell signaling, both 
of which are altered during melanoma initiation and progression. Increased levels of 
  viii 
5fC/5caC in these genes may be a contributing factor to this deregulation. Through these 
studies, we aim to identify distinct regions undergoing alterations in melanoma, which 
can serve as diagnostic and prognostic biomarkers. 
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INTRODUCTION 
 
In the past decade, the field of epigenetics has held the spotlight in the research 
arena. Scientific advancements, such as the Human Genome project, in conjunction with 
technological progressions have equipped researchers with the tools to elucidate one of 
the most fundamental questions in science: if all the cells within an organism contain an 
identical genetic code, what are the molecular players and mechanisms behind 
development and cellular differentiation?  
First described in 1942 by Conrad H. Waddington, epigenetics was the key to 
linking genotypic expression to phenotypic observations (Waddington, 1942). In his 
book, The Strategy of Genes, Waddington delves further into this concept, using the 
metaphor of a ball’s trajectory whilst traveling on surface (Waddington, 1957). Although 
it begins at a flat surface, dips, elevations and branch points alter the ball’s journey, 
influencing its final destination. The same principle can be applied to the trajectory of a 
cell during differentiation. The epigenetic landscape, as he called it, functions to direct 
the processes involved during cellular development. The terminal state of differentiation 
is not only due to the presence of specific gene products, but also to factors that influence 
which chreodes or trajectories a cell will travel through (Slack, 2002). While genes form 
the foundation, it is their interactions with the epigenomic landscape that ultimately 
determines the observed phenotype.   
Although far from complete, our understanding of the interplay between genetics 
and epigenetics has evolved greatly. Keeping in line with Waddington’s theory, we now 
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define epigenetics as the study of heritable changes in gene expression, without an 
accompanying change in the underlying DNA sequence (Berger, Kouzarides, Sheikhattar 
&Shilatifard, 2009). In the recent years, the main focus of epigenetic research has been 
on elucidating how these epigenetic changes are mediated and how they function in 
normal and disease states. The epigenetic landscape is comprised of both covalent and 
noncovalent modifications, which act to regulate the structure of chromatin. This 
regulation alters the accessibility of DNA, and therefore, impacts transcriptional activity 
(Goldberg, Allis & Bernstein, 2007). Three primary epigenetic mechanisms are involved 
in the control of gene expression: modification of histones, noncoding RNAs and DNA 
methylation. It is essential to note that unlike the genome, the epigenome is dynamic. 
Alterations to the aforementioned epigenomic markings occur throughout the course of 
normal development and can also be environmentally induced. 
 
HISTONES 
 
Within eurkaryotic organisms, the genetic material of a cell is arranged into 
highly organized DNA-protein complexes, termed chromatin. The nucleosome, which 
constitutes the building blocks of chromatin, is comprised of approximately 146 base 
pairs of DNA tightly wrapped around a histone core. This core is made up of an octamer 
of basic histone (H) proteins, containing two copies of each H2A, H2B, H3, and H4 
subunits (Luger, Mader, Richmond, Sargenet & Richmond, 1997). Each of the subunits 
has a similar 3D conformation and contains a tail region that penetrates outside of the 
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core region (Luger & Richmond, 1998). Unlike the other histones, the H1 subunit is 
associated with linking nucleosomes and is believed to have a role in stabilization (Luger, 
Mader, Richmond, Sargenet & Richmond, 1997).  
Chromatin is said to exist in two states, heterochromatin and euchromatin, which 
are easily distinguishable through histological staining. Heterochromatin is a 
characterized by a condensed chromosomal state, consisting of silenced genes and 
tandem repetitive elements. Euchromatin, however, is associated with open chromosomal 
areas, enriched in genes that are actively transcribed (Tamaru, 2010). Epigenetic 
modifications determine whether chromatin is in transcriptionally permissive or 
repressive state. Amino acid residues on the N-terminus of histone tails can undergo a 
multitude of post-translational modifications, including acetylation, methylation, 
ubiquitylation, phosphorylation, sumoylation, ADP ribosylation, deimination and proline 
isomerization (Kouzarides, 2007). The abovementioned histone modifications can work 
independently or in conjunction with other modifications to alter the chromatin state. 
Histone acetylation and methylation have been studied extensively and will be discussed 
here in greater detail. 
Histone Acetylation 
Acetylation of histones is a highly conserved epigenetic mark that has been 
encountered in eukaryotes of varying complexities—from single cell organisms such as 
yeast to more complex organisms such as mammals. It occurs exclusively on lysine 
residues and has been identified on the tails of all core histone subunits (Wang et al., 
2008). This modification has been universally accepted as a mark of active transcription 
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and is commonly encountered in euchromatin (Bernstein, Meissner & Lander, 2007; 
Kouzarides, 2007). The negatively charged acetyl group neutralizes the positive charge 
on lysine, thereby reducing the affinity of the histone for the DNA backbone. This results 
in relaxation and loosening of DNA, which grants access to factors necessary to initiate 
gene transcription (Zentner & Henikoff, 2013). Removal of the acetyl group exerts the 
opposite effect. Interestingly, acetylated histone tail residues have been found to associate 
with various regional targets.  While some have been found on the outskirts of promoter 
regions, others have been identified closer to transcriptional start sites and throughout the 
gene body (Wang et al., 2008).  
Acetylation is a dynamic process mediated by two groups of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDAC), which work in concert to 
establish and maintain proper levels of transcription (Zentner & Heinkoff, 2013).  Both of 
these enzymes commonly occur in multiprotein complexes, where the presence of other 
components regulates the specificity of the complex (Bannister & Kouzarides, 2011). 
HATs exert their function by transferring the acetyl group from acetyl coenzyme A to a 
lysine residue on the histone tail.  Type A HATs, including members of the diverse 
superfamilies Gcn5-related N-acetyltransferases (GNAT), MOZ, Ybf2/Sas3, Sas2, and 
TIP60 (MYST), and CREB-binding protein (CBP)/p300, are solely found in the nucleus 
and are associated with acetylation of histones bound to DNA (Sterner & Berger, 2000). 
Type B, which consists solely of variations of the HAT1 enzyme, are found both in the 
cytosol and nucleus, and their primary function is the acetylation of newly synthesized 
histones (Bannister & Kouzarides, 2011).  
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HDACs are responsible for the opposing reaction, leading to the removal of the 
acetyl group. This reestablishes the positive charge, strengthening the DNA-histone tail 
bond. HDACs can be grouped into four classes based on structural homologies. Those 
belonging to classes 1, 2, and 4 also referred to as the “classical family,” rely on the use 
of a zinc-catalyzed hydrolysis of the amide bond to remove the acetyl group (Gallinari et 
al., 2007). Class 4, the Sirtuin (Sir) family, bares no structural homology to the other 
classes and is dependent on a nicotinamide adenine dinucleotide (NAD+) cofactor for its 
enzymatic activity. The deacetylation activity of the Sir family is carried out through the 
hydrolysis of NAD+, which results in the transfer of the acetyl group to the adenosine 
diphosphate (ADP)-Ribose component (Saunders & Verdin, 2007). Thus through the 
regulation of histone acetylation, the cell is able to exert control over gene expression, 
with the presence of histone acetylation indicating active genes.  
Histone Methylation 
Histone methylation is also a highly conserved epigenetic mark, which is highly 
dynamic in its nature. Unlike acetylation, multiple methyl groups can be added to both 
arginine and lysine residues on the histone tails of subunits H2A, H3 and H4 (Zhao & 
Garcia, 2015). Methyl groups do not carry a charge and are quite stable, therefore, their 
addition does not alter the net charge of the moiety. Because of this, methylated histone 
marks can be associated with both gene expression and repression (Bannister & 
Kouzarides, 2011).   
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Arginine Methylation 
Methylated arginines can exist in three states: monomethylated, symmetrically 
dimethylated and asymmetrically dimethylated. The addition of each methyl group 
occupies a bonding site on nitrogen and alters the overall spatial configuration of the 
residue, therefore, limiting its interactions with outside players. Although there are 
approximately 40 different recognized methylation sites, the function of most of them 
have not been consistently or accurately classified (Gaytari & Bedford, 2014). Many, 
however, are believed to be “active” marks (Zhao & Garcia, 2015). 
The enzymes responsible for the methylation reaction, protein arginine methyl 
transferases (PRMTs), can be divided into 3 classes depending on the generated products. 
Classes I, II and III can all catalyze the formation of monomethylarginine. Class I can 
further methylate to generate asymmetrical dimethylarginine, while class II is responsible 
for the formation of symmetrical dimethylarginine (Cheng, 2014). The enzymatic activity 
of PRMTs lies within a highly conserved catalytic core, which transfers the methyl group 
from S-adenosylmethionine (SAM) to a nitrogen on the guanidine group (Bedford & 
Richard, 2005). Interestingly, PRMTs are not histone specific and also have the ability to 
methylate arginine residues within various protein structures.  
Unlike the methylation process, the demethylation of arginine residues is not as 
straightforward. Peptidylarginine deiminase enzymes (PADI) are able to act on methyl 
arginine through demethylimination; they catalyze the hydrolysis of the methylated 
arginine into citrulline. Because it does not reinstate an unmodified arginine, PADI is not 
considered a true demethylase (Klose & Zhang, 2007). Another enzyme, Jumonji 
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domain-containing 6 protein (JMJD6), has been at the center of the demethylation debate 
since its discovery in 2007. JMJD6 is an iron and 2-oxoglutarate dependant dioxygenase, 
which was shown to demethylate both mono and dimethylated arginines at H3R2 and 
H4R3 (Chang, Chen, Zhao & Bruick, 2007). Replication of these findings has produced 
conflicting results on its true ability to demethylate arginines, however, its role in other 
cellular processes, such as mRNA splicing, has emerged (Böttger et al., 2015). 
Lysine Methylation 
Lysine methylation, which can be encountered on the tails of H3 and H4, can 
occur in a mono, di, or trimethylated forms. As mentioned above, the methyl groups do 
not alter the overall charge of the residue, but influence the overall structure, and thus 
impact the resulting protein interactions. The various methylated lysine markings have a 
characteristic association with transcriptional states. For example, trimethylated forms of 
H3K4 and H3K36 are associated with actively transcribed genes and are found 
surrounding transcriptional start sites. On the other hand, H3K9me2&3, H3K27me2&3 
and H4K20me3 are associated with gene repression (Barkski et al., 2007; Zhao and 
Garcia, 2015).  
Methylated lysine residues associated with both gene activation and silencing 
have been found to be associated with, what has been termed, bivalent domains. First 
characterized by Bernstein et al., embryonic stem cells were found to contain stretches of 
genes that were abundant in the repressive mark, H3K27me3, but also contained smaller 
patches of the activating mark, H3K4me3. Although these regions were found to be 
associated with low levels of gene expression, they harbored the ability to become 
 8 
activated under the proper differentiation cues. Once differentiated, these regions 
resolved into only one of the markings (Bernstein et al., 2006). This phenomenon serves 
as a reminder that the epigenome is not only able to undergo alterations, but is also 
dependent and associated with the cross talk amongst other epigenomic markings.  
Histone lysine methyltransferases (HKMTs) are the enzymes responsible for 
transferring the methyl group from S-adenosyl-L-methonine onto the amino group on 
lysine. The catalytic activity of HKMTs is found within a highly conserved region called 
the Su(var)3-9, Enhancer-of-zeste, Trithorax domain (SET) domain (Bannister and 
Kouzarides, 2011). SET domains fold into a highly unique structure, consisting of a 
pseudo knot surrounded by sheets of beta strands. The sequence homology of this domain 
is the basis for the classification of HKMTs into 7 subgroups. The variation in the protein 
sequences of the active site is responsible for the high specificity of HKMTs; it 
determines which lysine residues can be modified and to which degree methylation can 
occur (Dillion, Zhang, Trievel & Cheng, 2005). 
Demethylation of lysine residues can occur via two separate mechanisms, 
oxidation or hydroxylation, and is dependent on the degree of methylation. Lysine-
specific demethylase 1 (LSD1) was the first described lysine demethylase, which 
preferentially acts on H3K4me2/me1 in promoter regions (Chosed & Dent, 2007; Shi et 
al., 2004). Interestingly, interactions with the androgen receptor alter LSD1’s substrate 
preference, leading to demethylation of H3K9me2/1 (Metzger et al., 2005). Using flavin 
adenine dinucleotide (FAD) as cofactor, LSD1 oxides the amine group to an imine 
intermediate, which subsequently undergoes hydrolysis and completes demethylation. 
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Because LDS1 requires protonated nitrogen, it can only demethylate di or monomethyl 
lysine (Shi et al., 2004). Another amine oxidase, lysine-specific demethylase 2 (LSD2), is 
closely related to LSD1. It also demethylates H3K4me2/me1, however, it acts within the 
body of target genes (Fang et al., 2010). Although LSD2 carries out its demethylation 
functions in a similar manner, it does not associate with CoREST, a corepressor protein, 
as does LSD1 (Karytinos et al., 2009). Hence, having both LSD1 and LSD2 is crucial for 
the demethylation of lysine. 
Methylated lysines can also undergo hydroxylation by enzymes containing 
Jumonji-C domains (JMJC). Jumonji-C domain containing histone demethylases (JHDM) 
require iron and alpha-ketoglutarate as cofactors and are able to hydrolyze the 
methylamine bond, producing formaldehyde as a byproduct (Tsukada et al., 2006). 
Similar to LDS1, JHDMs are highly specific and are only able to demethylate specific 
lysine residues. They do not, however, require protonated nitrogen. Thus, some JHDMs, 
specifically JMJD2/JHDM3, have the ability to demethylate trimethylated residues 
(Whetstine et al., 2006). 
NON-CODING RNAS 
 
Although approximately 90% of the eurkaryotic genome is transcribed into 
mRNA, the ENCODE consortium has brought to light that only 1-2% of these code for 
proteins. The remaining 88-89% is transcribed into what is termed as a non-coding RNAs 
(ncRNA) (Birney et al., 2007). Non-coding RNAs are defined as functional RNA 
molecules that are transcribed from DNA but do not code for proteins. They can be 
divided into two main categories based on function: infrastructural and regulatory 
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(Kaikkonen, Lam, & Glass, 2011). Infrastructural ncRNAs are involved in basic 
transcriptional functions and include ribosomal RNAs, transfer RNAs and small nuclear 
RNAs. Regulatory ncRNAs, however, are considered a primary epigenetic mechanism 
involved in the influence of gene expression. They can be further characterized into 
microRNAs (miRNA), small interfering RNAs (siRNA) and long non-coding RNAs 
(lncRNA) (Kaikkonen, Lam, & Glass, 2011; Morris & Mattick, 2014).  
Long Noncoding RNAs 
Long noncoding RNAs are by far the most abundant class of ncRNAs. They are 
defined as any ncRNA that is greater than 200 nucleotides, which may or may not have 
undergone polyadenylation or splicing post transcription. Many smaller ncRNAs have 
been shown to originate as lnRNAs that have been modified (Morris & Mattick 2014). 
They can be classified as antisense, intronic, bidirectional, intergenic, overlapping or 
descriptive relative to the location of the closest protein coding gene (Mattick & Rinn, 
2015). LncRNAs have been found to be involved in a variety of processes, including 
regulating protein synthesis, alternative splicing and cellular architecture. However, more 
recently, its functions in epigenetics and cell differentiation and transcriptional silencing 
have begun to emerge (Bohmdorfer & Wierzbicki, 2015; Deng & Sui, 2013). A classic 
example is the role of HOX transcript antisence RNA (HOTAIR), a long intergenic 
noncoding RNA involved in the regulation of chromatin state. Transcribed from the 
HOXC locus, the 5’ domain of HOTAIR has been shown to bind to the polycomb 
repressive complex 2, which is involved in methylating the repressive histone mark 
H3K27. The 3’ end, however, was shown to bind to the CoREST/REST repressor, which 
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is associated with LSD1 and leads to the demethylation of H3K4me2. By linking the 
process of histone methylation and demethylation, HOTAIR and other lncRNAs are able 
to affect transcription and chromatin state genome-wide (Tsai et al., 2010). 
MicroRNAs and SiRNAs 
MicroRNAs have been classically seen as a regulatory mechanism for 
endogenous genes. At only 20-24 nucleotides long, miRNAs regulate messenger RNAs 
(mRNA) posttranscriptionally by either repressing the transcription of or degrading the 
target mRNA. They are typically transcribed in conjunction with a protein or multiple 
miRNAs and undergo capping and polyadenylation (Mattick & Makunin, 2006). These 
primary transcripts form a characteristic stem and loop structure, which undergo 
processing by Drosha and Dicer to produce double stranded miRNAs, with highly exact 
ends. One copy of the miRNA binds to the Agonaute (Ago) protein on the RNA-induced 
silencing complex (RISC), which acts as a guide and adaptor for the complex to bind 
onto mRNA in the 3’ untranslated region. Complimentary miRNA binding is only 
required for 2-8 nucleotides, which comprise the “seed region,” the remaining 
nucleotides can have bulges and mismatching pairing. The resulting effect of this non-
perfect binding is translational repression, and is considered to be the primary function of 
miRNA. Non-perfect binding can also lead to mRNA degradation through decapping, 
deadenylation and exonucleolytic digestion. If perfect binding between the miRNA and 
mRNA does occur, the mRNA transcript is cleaved via Ago. In summary, miRNAs 
regulate gene expression in a negative manner by degrading mRNA transcripts or halting 
mRNA translation (Carthew & Sontheimer, 2009; Morris & Mattick, 2014).  
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SiRNAs are also 20-24 nucleotides long, however, they are products of linear, 
perfectly base-pair matched double stranded RNAs. Historically, it was believed that 
siRNAs were introduced into the cytoplasm exogenously through transgenes or viruses, 
however, it has been shown that they can be produced from endogenous genes as well 
(Kaikkonen, Lam, & Glass, 2011). SiRNAs undergo the same processing mechanisms as 
miRNAs. Once bound to Ago, they bind to mRNA in a perfect or imperfect 
complementary fashion. Unlike miRNA, siRNA preferentially binds with its perfect 
complement, which leads to Ago-catalyzed cleavage of the mRNA. This process also 
allows for generation of secondary double stranded siRNAs, which can further amplify 
these actions. Preference to perfect base pairing also means siRNAs can silence the 
transcription product of their native genomic loci.  When bound imperfectly, siRNA is 
indistinguishable from miRNA and leads to repression of transcription or exonucleolytic 
degradation (Morris & Mattick, 2014). Astonishingly, siRNAs have also been shown to 
meditate heterochromatin formation. SiRNA bound RISC complexes migrate to the 
nucleus, where they recognize and bind newly synthesized transcripts. The association 
with RISC triggers the methylation of H3K9, which signals for recruitment of the Swi6 
protein and leads to the compaction of the chromatin (Carthew & Sontheimer, 2009). 
Whether through its role in Ago-catalyzed cleavage or heterochromatin formation, 
siRNAs play a large role in repressing gene expression. 
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DNA METHYLATION 
 
Methylation at the 5th position of the cytosine (C) nucleotide is considered the 
“5th base” of DNA and is a key player in epigenetic regulation. This covalent 
modification is localized to cytosines adjacently bound to guanine (G) in what is called 
CpG dinucleotides. Although 5-methylcytosine (5mC) constitutes only approximately 4% 
of the cytosine bases, 70-80% of CpG sites in mammalian genomes are methylated (Bird, 
2002; Breiling & Lyko, 2015). CpG islands (CGI) are the exception to this observation. 
Although their precise definition is quite variable, CpG islands are regions of 200-1000 
base pairs that are highly enriched in both CpGs and single cytosine/guanine nucleotides 
(Illingworth & Bird, 2009; Jones, 2012; Laird, 2010; Smith & Meissner, 2013; Suzuki & 
Bird, 2008). Characteristically unmethylated, CpG islands are primarily localized in the 
promoters of genes, although orphan CGIs can also be found in intragenic and intergenic 
regions. 70 percent of genes have been found to have promoter-associated CGIs, 
especially those involving housekeeping genes, tissue-specific genes, and genes involved 
in development (Deaton & Bird, 2011; Illingworth & Bird, 2009). 
The presence of DNA methylation is traditionally viewed as a mark involved in 
silencing gene expression, as seen from its role in imprinted genes, X chromosome 
inactivation and transposon silencing (Bestor, Edwards, & Boulard, 2015; Yang & Wang, 
2016). The methyl groups, which are typically present on both the sense and antisense 
strands, can either act to hinder the binding of transcription factors or act as an 
identifying mark for the binding of repressor complexes (Breiling & Lyko, 2015; Li & 
Zhang, 2014; Smith & Meissner, 2013).  
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The most well understood example of the hindering effect of methylation occurs 
at the imprinting control region of the H19/Igf2 locus. Maternally, this region is 
unmethylated, allowing for the binding of CTCF protein. Once bound, CTFC blocks the 
interaction between the promoter and enhancer, resulting in the silencing of the maternal 
insulin like growth factor (Igf2). In the paternal chromosome, the imprinting control 
region is methylated, therefore, interfering with the binding of CTCF. The enhancer can 
then act upon the promoter, which results in the activation of Igf2 (Hark et al, 2000). 
Although this example illustrates a gene that subsequently becomes activated, the 
principle that methylation interferes with DNA binding factors can also result in gene 
silencing. 
The methyl-CpG binding domain family (MBD), conversely, specifically 
recognizes and binds to these methylated domains. The MBD family consists of 5 
members: methyl CpG binding protein 1 (MeCP1), methyl CpG binding protein 2 
(MeCP2), methyl-CpG binding domain protein 1 (MBD1), methyl-CpG binding domain 
protein 2 (MBD2) and methyl-CpG binding domain protein 3 (MBD3). These proteins all 
contain a highly conserved binding motif but have a high degree of variation in other 
structural features (Hendrich & Bird, 1998). These proteins exert their actions through 
their associations with corepressor complexes such as Sin3a and NuRD. In this way, 
DNA methylation acts as a marker to trigger gene repression through the recruitment of 
corepressor complexes (Bird & Wolffe, 1999).  
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De novo and Maintenance Methylation  
A class of enzymes known as DNA methyltransferases (DNMTs) are responsible 
for the methylation of cytosine. As with histone methyltranferases, DNMTs catalyze the 
transfer of a methyl group from S-adenosylmethionine (SAM) onto the carbon of 
cytosine. There are three mammilian DNMTs that have the ability to methylate DNA: 
DNMT1, DNMT3A and DNMT3B. Although there are variations in the N termninal 
domain, there are 10 highly conserved motifs in the C terminal that give these enzymes 
their catalytic properties (Subramaniam, Thombre, Dhar, & Anant, 2014). DNMT1 was 
the first described DNA methyltransferase and is the most prominent DNA 
methyltransferase. DNMT1 is present in both fetal and adult tissues and is primarily 
involved in maintenance methylation (Robertson et al., 1999). Maintenance methylation 
occurs primarily during the S phase of mitosis and involves restoring complete 
methylation to a hemimethylated CpG (Arand et al., 2012). De novo methylation of CpG 
sites is carried out by DNMT3A&B (Okano et al., 1999). These enzymes are typically 
absent in active gene regions, preferentially localizing to regions of dense and methylated 
CpGs. Surprisingly, DNMT3B was also shown to methylate CpGs located within the 
bodies of active genes (Baubec et al., 2015). Even though the mode of methylation 
remains consistent between the DNMTs, differences in their preferential targets give rise 
to the methylation patterns observed genome-wide. 
Demethylation Through TET-mediated Oxidation and TDG excision 
Unlike methylation, the process of demethylation is not as straightforward and produces 
various intermediates. The process is mediated through the Ten-eleven translocation 
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(TET) family proteins, which are dependent on iron and alpha-ketoglutarate for their 
oxidative properties (Tahiliani et al., 2009). TET proteins have been shown to oxidize 5-
methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and further into 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011; Tahiliani et al., 
2009). The TET protein family consists of three members: TET1, TET2, and TET3, all of 
which are capable of carrying out these oxidative transformations (Kohli & Zhang, 2013). 
TET1 is primarily expressed in ESCs and primordial germ cells, and its expression is 
believed to be maintained by pluripotency-related transcription factors (Wu & Zhang, 
2014). Out of the three, TET2 is the most widely expressed in adult tissues. Although it 
can be detected alone, it is usually coexpressed with one of the other family members 
(Lorsbach et al., 2003). TET3 has very limited expression in adults, however, it is highly 
abundant in oocytes and zygotes due to its role in embryonic reprogramming (Gu et al., 
2011). The TET family proteins are therefore essential for producing the various 
oxidative products of 5mC. 
Once TET-mediated oxidation of 5mC to 5fC/5caC has occurred, excision and 
repair of these bases occurs via the base-excision repair (BER) pathway, which is 
triggered by thymine DNA glycosylase (TDG). TDG is able to recognize and bind 
specifically to 5fC and 5caC modified residues (He et al., 2011; Shen et al., 2013). It 
catalyzes the cleavage of the N-glycosidic bond between 5fC/5caC and the deoxyribose, 
creating an abasic site. The BER pathway then acts to replace this abasic site with an 
unmodified cytosine, completing the demethylation cycle (Bellacosa & Drohat, 2015). 
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Thus, the TET, TDG and BER pathway work in conjunction to carryout demethylation 
by replacing a modified cytosine with a new, unmethylated one.  
DNA methylation is a very dynamic process, undergoing various alterations 
throughout development, aging and environmental exposures. The most drastic 
alterations occur during fertilization and embryogenesis. During this time, the epigenome 
undergoes a major reprogramming, with almost a complete erasure of DNA methylation 
in both the maternal and paternal genome. This process is mediated via passive dilution 
and active demethylation (Li & Zhang, 2014). Demethylation by passive dilution occurs 
in the maternal oocyte in a replication-dependant manner (Rougier et al., 1998). The lack 
of DNMT1 in the maternal nucleus during these initial stages hinders maintenance 
methylation. Upon subsequent replication, the inability to methylate newly synthesized 
stands leads to asymmetrical methylation and eventually lack of methylation (Howell et 
al., 2001). The paternal and the maternal genome are subjected to active demethylation 
via TET3 (Guo et al., 2014; Mayer et al., 2000; Santos et al., 2002). By the time the 
embryo reaches blastocyst stage, remethylation of the genome occurs and continues 
throughout the post implantation period (Messerschmidt, Knowles & Solter, 2014). The 
processes and players involved in regulating the methylome during embyrogensis are a 
snapshot of how this epigenetic mark can undergo alterations in response to intrinsic or 
extrinsic cues.  
TET-mediated Modification 
As mentioned above, the TET enzymes are able to oxidize 5mC into 3 other 
modified bases: 5hmC, 5fC, and 5caC. These modifications are believed to not only be 
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demethylation intermediates, but to also be stable modifications (Bachman et al. 2014, 
2015)  
Now known as the 6th base of DNA, 5-hydroxymethylcytosine (5hmC) was first 
described in 1953 in bacteriophages (Wyatt & Cohen, 1953). Since then, 5hmC has been 
detected in a variety of cell types and tissues, with levels ranging from 0.03-0.7% 
(Globisch et al., 2010). It is present at high levels in embryonic stem cells, although the 
levels are believed to decrease with differentiation (Ruzov et al., 2011). The levels of 
5hmC are also tissue-specific. Brain and renal tissue have been shown to be enriched in 
5hmC, while its presence is minimal in heart and breast tissue (Kriaucionis & Heintz, 
2009; Li & Liu, 2011). As seen with its precursor, it is believed that 5hmC has a role in 
governing gene expression. It is frequently localized in the gene bodies of highly active 
genes (Song et al. 2011; Wu et al., 2011; Xu et al., 2011). 5hmC is also enriched at distal 
regulatory elements, such as active enhancers, supporting its role in gene transcription 
(Yu et al., 2012). On the other hand, there is an inverse relationship between the 5hmC 
density at promoter regions and gene expression. Higher modification density in this 
region is associated with genes that have lower expression (Xu et al., 2011). Together, 
these findings illustrate the complexity and regional dependence between 5hmC and gene 
expression. 
5fC and 5caC have been found to be stable modifications, which are present in 
both mouse embryonic stem cells (mESC) and adult tissues (Bachman et al., 2015). In 
stem cells, 5fC and 5caC have been shown to exist at levels of around 2% and 0.3%, 
respectively, of total 5-hmC residues (Ito et al., 2012). It is no surprise that these 
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modifications also play a role in the regulation of gene transcription. Various studies have 
shown that 5fC/5caC is enriched at distal regulatory elements, such as poised/active 
enhancers, DNase hypersensitive sites and transcriptional regulators (Shen et al,2013; 
Song et al. 2013; Wu et al., 2014). Futhermore, exploration of 5fC and 5caC levels has 
strengthened the principle of TET/TDG/BER mediated demethylation and their role in 
gene expression.   
A newly established technique, methylase-assisted bisulfite sequencing (MAB-
seq), can be used to map the genome wide distribution of 5fC/5caC at single base pair 
resolution (Neri et al., 2015; Wu et al., 2014). In standard bisulfite sequencing (BS-seq), 
5mC and 5hmC resist deamination and are sequenced as cytosine (C). Unmethylated 
cytosine, 5fC and 5caC undergo deamination to uracil (C/5fC) or 5caU (5caC), both of 
which are sequenced as thymine (T). Consequently, standard bisulfite sequencing 
methods cannot distinguish C, 5fC and 5caC (Neri et al., 2015; Song et al. 2013; Wu et 
al., 2014). MAB-seq, when paired with basic BS-seq, is able to distinguish these 
modifications by utilizing the methylation of the cytosine prior to bisulfite treatment. In 
this approach, M.SssI, a CpG methyltransferase, is used to specifically methylate 5C to 
5mC, which is then detected as C in sequencing, whereas 5fC/5caC are read as thymine 
(T) (Neri et al., 2015; Wu et al., 2014). Therefore, MAB-seq directly detects the 
abundance and distribution of 5fC+5caC abundance at base-pair resolution genome-wide. 
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CANCER: THE RESULT OF EPIGENETIC DEREGULATION 
 
Epigenetic regulation is an important constituent in the expression of both genetic 
information and proteins required for cellular function. In order to maintain a healthy, 
noncancerous state, the proper expression of proteins involved in cell growth and death is 
vital. Deregulation of epigenetic factors has been shown to lead to improper expression of 
genetic factors and eventually to cancer.  
Alterations in the methylation patterns of  DNA are a hallmark of oncogenic 
transformation. Inactivation of tumor suppressor genes through promoter 
hypermethylation is one of the most well characterized occurrences in cancer. This 
aberrant methylation however is not widespread–tumor cells of various cancer types 
exhibit global hypomethylation (Jones & Baylin, 2002).  Another potential hallmark, the 
loss of 5hmC, has been recently proposed for melanoma (Lian et al., 2012). Most recently, 
a gain in 5caC levels has been observed in breast cancer and gliomas (Eleftheriou et al., 
2015). These oncogenic-associated alterations to the methylome do not occur 
spontaneously. The enzymes involved in maintaining and regulating the methylome, 
DNMT and TET respectively, have been shown to play roles in transforming a stable 
epigenome into one associated with cancer (Jones & Baylin, 2002; Scourzic, Mouly & 
Bernard, 2015). The epigenetic alterations described above will, subsequently, be 
described in the context of melanoma. 
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MELANOMA 
Introduction 
Melanoma, also referred to as malignant or cutaneous melanoma, is a form of skin 
cancer arising from epidermal melanocytes. Although it comprises only 2% of skin 
cancers, melanoma accounts for the majority of skin cancer induced deaths. The 
incidence rate of melanoma has steadily increased over the past 30 years, with 75,000 
new projected cases in the US in 2015 (“Detailed Guide Melanoma Skin Cancer | 
American Cancer Society,” n.d.). Its high mortality rate combined with its increasing 
prevalence makes this preventable cancer a major public health concern. There are 
several factors that increase one’s risk of developing melanoma, including fair colored 
skin, extensive exposure to UV rays, family history and having nevi. Melanomas are 
staged in accordance to the guidelines established by the American Joint Committee on 
Cancer, which takes into account the thickness of the tumor, number of lymph nodes 
affected and if metastasis has occurred. The mitotic rate and presence of ulceration are 
also important attributes in determining pathological severity (“Detailed Guide 
Melanoma Skin Cancer | American Cancer Society,” n.d.). Because of the increasing 
prevalence and high mortality rate, malignant melanoma will continue to be at the 
forefront of the cancer community. 
The pathogenesis underlying melanoma stems from the deregulation of cell 
signaling pathways that mediate cell proliferation, differentiation and apoptosis. Both 
genetic and epigenetic factors have been implicated in the development and progression 
of melanoma and will be addressed below.  
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Genetic Alteration 
Familial melanoma accounts for 10% of total cases and arises from genetic 
mutations. Both activating and inactivating mutations have been described in familial 
melanoma and are limited, mainly, to 8 genes. Their involvement can be grouped into 
either cell cycle/differentiation or telomerase function (Aoude, Wadt, Pritchard & 
Hayward, 2015).  
CDKN2A, CDK4, BAP1 and MITF are genes that are commonly mutated in 
familial melanoma and are involved in regulating the cell cycle or differentiation (Aoude, 
Wadt, Pritchard & Hayward, 2015). Mutations in cyclin-dependent kinase inhibitor 2A 
(CDKN2A) are the most prominent and are responsible for 39% (ranges from 20-57% 
depending on continent) of familial cases (Goldstein et al., 2007). The CDKN2A locus is 
located on chromosome 9 and codes for two tumor suppressor proteins, p14 and p16, 
which trigger processes involved in controlling cell proliferation (Griewank et al., 2014). 
Mutations in the gene coding for cyclin-dependent kinase 4 (CDK4) are more rare and 
have only been identified in 17 families. This gene codes for the catalytic subunit of a 
seronine/theronine kinase, which controls cell cycle progression (Puntervoll et al., 2013). 
The BRACA1 associated protein 1 (BAP1) gene encodes for a deubiquintinase that is 
involved in a variety of cell processes, including growth and proliferation (Matatall et al., 
2013; Jensen et al., 1998; Yu et al., 2010). It is commonly referred to as a tumor 
suppressor and is also involved in repairing double strand breaks in DNA (Yu et al., 
2014). Mutations in the transcription factor coding gene mitophthalmia-associated 
transcription factor (MIFT) have been identified in 10-20% of malignant melanoma 
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tumors (Garraway et al., 2005). MIFT is involved in a variety of processes including 
melanocyte differentiation and melanosome synthesis. Interestingly, MITF has also been 
shown to target CDKN2A (Cheli, Ohanna, Ballotti & Bertolotto, 2010). Collectively, 
mutations in these genes lead to dysregulation of the the cell cycle, resulting in increased 
proliferation of melanocytes. 
TERT, ACD, POT1 and TERF2IP are genes that are implicated in familial 
melanoma and are involved in telomerase function (Aoude, Wadt, Pritchard & Hayward, 
2015). Telomerase reverse transcriptase (TERT) is the gene responsible for encoding the 
catalytic subunit of telomerase reverse transcriptase. The primary role of this enzyme is 
to maintain telomeric length. In melanoma, there is a C to T mutation in the TERT 
promoter region, which creates a novel transcription factor binding motif (Horn et al., 
2013; Huang et al., 2013). The enzyme is consequently overexpressed, allowing the cell 
to maintain telemetric length and avoid senescence or apoptosis (Griewank et al., 2014; 
Huang et al., 2013; O’Sullivan & Karlseder, 2010). Adrenocotical dysplasia homolog 
(ACD), protection of telomerase 1 (POT1), and telomeric repeat binding factor 2 
interaction protein (TERF2IP) code for three of the proteins that comprise the shelterin 
complex. This complex regulates the elongation of telomeres by directing the interaction 
between the telomerase complex and teleomeres. Mutations in any of the three enzymes 
alter the shelterin complex and, therefore, have a negative impact on telomeric length 
(Aoude, Wadt, Pritchard & Hayward, 2015; O’Sullivan & Karlseder, 2010). Taken 
together, mutations in these genes result in aberrant maintenance of telomeres, resulting 
in immortal cells. 
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Along with the aforementioned perturbations, mutations in other key signaling 
pathways have been encountered in sporadic melanoma including those involved in the 
MIFT activation and epidermal growth factor receptor (EGFR) signaling. The B-Raf 
proto oncogene (BRAF) is frequently implicated in melanoma and is associated with a 
poor prognosis when detected in Stage III or IV (Mann et al., 2013). BRAF mutations 
have been found in 40-50% of melanomas and normally constitutes the switching the 
valine at the 600th codon for another amino acid, most commonly glutamic acid (Ascierto 
et al., 2012; Heinzerling et al., 2013). This mutation leads to the activation the BRAF 
serine/theronine kinase, which acts on the mitogen-activated protein kinase (MAPK)/ 
extracellular signal-related kinases (ERK) signaling pathway, leading to uncontrolled 
growth and proliferation (Davies et al., 2002). Through studying the genetics underlying 
melanoma, we are able to better understand how and why these mutations result in 
oncogenic transformations.  
Epigenetics and Melanoma 
The epigenetic alterations observed in melanoma encompass all areas on the 
spectrum, including DNA methylation and its subsequent modifications, histone 
modifications and non-coding RNAs. It is important to remember that there is a lot of 
interplay within these classes. The methylome has the most relevance to this project and 
will be discussed in more depth.  
As previously stated, a characteristic observation in cancer is global DNA 
hypomethylation, with hypermethylation occurring at promoter regions of key cancer 
related genes. This observation holds true for malignant melanoma. A recent review cited 
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over 100 genes involved in cell growth and tumor suppression that undergo 
hypermethylation in their promoter regions (Sarkar et al., 2015). One of the most 
frequently epigenetically altered genes is the retinoic acid recetor- 2 (RAR- 2). This 
gene typically encodes for a nuclear receptor/tumor suppressor that, when activated by all 
trans retinoic acid (ATRA), inhibits the growth of melanocytes (Fan et al., 2010). 70% of 
melanocytic tumors exhibit hypermethylation in the RAR-2 promoter, thereby 
inactivating the tumor suppressive functions of the gene (Hoon et al., 2004). Interestingly, 
hypermethylation of CKND2A, which is implicated in familial melanoma, has been 
shown to occur in sporadic melanoma (Straume et al., 2002). Hypomethylation in 
melanoma has not been as well studied much less. It has, however, been shown to have 
an activating effect on transposable elements, such as LINE, increasing the tumors 
metastatic potential and resulting in poorer prognosis (Ecsedi et al., 2013; Hoshimoto et 
al., 2012). Because the role of DNA methylation is critical in gene expression, it is 
important to understand the role aberrant methylation plays in malignant melanoma. 
Identifying of the loss of 5hmC as a melanoma biomarker has been revolutionary 
in understanding the epigenetics underlying the disease. The genome-wide loss of 5hmC 
in melanoma, as compared to benign nevi, occurs primarily in introns and intergenic 
regions. The dramatic decrease in 5hmC levels is clearly observed in the transition from 
benign nevus to thin primary melanoma, and the level continues to decrease with disease 
progression. There is also a negative correlation of 5hmC with tumor staging (Lian et al., 
2012). Another characteristic used to histologically differentiate oncogenic melanocytes, 
nuclear size, has been shown to be associated with 5hmC levels as well. Importantly, the 
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kerotinocytes in the cellular environment surrounding melanoma were also impacted, 
showing a similar decrease in this epigenetic marker (Larson et al., 2014). 
5hmC levels, however, cannot undergo alterations spontaneously; there is an 
enzymatic component governing this observed changed. TET family proteins are 
responsible for maintaining the methylome landscape, and therefore, alterations in their 
levels translate into the deregulation of the various cytosine modifications (Coutinho et 
al., 2015; Huang et al., 2013; Ko et al., 2010; Scourzic, Mouly & Bernard, 2015).  It has 
been shown that all of the TET family proteins, especially TET2, undergo 
downregulation in melanoma (Lian et al., 2012). Genomic analysis has revealed that 
approximately 15% of melanoma cases harbor a mutation in TET2 (Lee et al., 2015). 
Furthermore, it has been shown that changes in TET cofactors can also translate into TET 
dysfunction. Isocitrate dehydrogenase (IDH) is the primary enzyme involved in the 
formation of alpha-ketoglutarate, an essential cofactor for TET2 function.  Mutations in 
the gene coding for this enzyme lead to the subsequent formation of 2-hydroxyglutarate, 
which acts as an antagonist and renders TET2 inactive (Xu et al., 2011). IDH mutations 
occur in 10% of melanomas, however, when in conjunction with TET2 mutations, they 
comprise 21% of the mutations observed in melanocytic tumors (Lee et al., 2015; 
Shibata, Kokubu, Miyamoto, Sasajima, & Yamazaki, 2011). Interestingly, the mutation 
that occurs in IDH corresponds to the UVB-signature mutation, a C to T point mutation, 
which is implicated in disrupting gene function in melanoma (Lee et al., 2015). 
The dynamic relationship between TET/5mC/5hmC has been well established in 
terms of its occurrence and role in cancer development, however, very little is known 
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about how 5fC and 5caC fit into this archetype. There is a need for a more 
comprehensive understanding of these epigenetic marks and their potential role in cancer 
development and progression.  Using methylase-assissted bisulfite sequencing technique 
(MAB-seq), this project aims to characterize the potential role these epigenetic marks 
have in the transformation of melanocytes into malignant melanoma 
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SPECIFIC AIMS 
With the incidence rate continuing to steadily increase, malignant melanoma 
poses a significant burden on our healthcare and public health infrastructure. Because 
genetic mutations account for only 10% of these cases, there is a demand to better 
understand the epigenetics underlying this malignant transformation. Our lab has 
previously shown that the loss of 5-hydroxymethylcytosine (5hmC) correlates with the 
development of malignant melanoma. This decrease is observed throughout the transition 
from benign nevus to thin primary melanoma and continues to decrease with progression 
of the disease. In this study, we aimed to understand whether the levels of the oxidative 
products of 5hmC, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) are affected in 
the malignant melanoma cell lines, A2058 and Mel Juso, and how these marks may 
contribute to disease development. To test this hypothesis I will: 
1. Use MAB-seq to map 5fC/5caC throughout the whole genome at base 
pair resolution  
2. Characterize the levels and distribution patterns of 5fC/5caC 
3. Identify specific genomic regions in which these signatures vary 
between the cell lines 
With these studies, we hope to gain insight into the role of 5fC/5caC in 
melanoma. By characterizing the levels and distributional patterns of these marks, we 
will be able to better comprehend their influence on gene transcription and oncogenic 
transformation. 
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METHODS  
EXPERIMENTAL METHODS 
Cell Culture 
Mel Juso is a malignant melanoma cell line derived from a primary melanocytic 
tumor. A2058 is as well a malignant melanoma cell line, which is derived from a lymph 
node metastasis. Both cell lines were cultured in Dulbecco Modified Eagle Medium 
(DMEM), supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin-
Streptomycin. Cells were incubated at 37ºC and 5% CO2 in a humidified atmosphere. 
DNA Isolation 
A2058 and Mel Juso cells were harvested and incubated overnight at 55ºC in 
digestion buffer (60mM Tris pH 8.0, 100mM EDTA 0.5% SDS) with proteinase K (20 
mg/mL). DNA was extracted using phenol-chloroform according to recommended 
protocol.  
Methylase-assisted Bisulfite sequencing (MAB-seq) 
As aforementioned, MAB-seq is a technique that takes advantage of BS-
sequencing properties to map the distribution of 5fC and 5caC at base pair resolution 
genome wide. MAB-seq was performed as described by Neri et al. (2015). Briefly, 1 µg 
of DNA was methylated using M.SssI (New England BioLabs). DNA libraries were 
prepared according to the Illumina protocol (TruSeq DNA PCR-Free Library Preparation 
Kit). Adaptor ligated libraries were treated with M.SssI (New England BioLabs) to 
methylate bases introduced through end repair, and then amplified for 15 cycles using 
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KAPA HiFi Hotstart Uracil+ Readymix PCR Kit (KAPA Biosystems) to methylate the 
bases introduced through end repair. Libraries were sequenced using HiSeq x10 System 
(Illumina). 
BIOINFORMATIC ANALYSIS 
MAB-seq M.Sssl methylation efficiency and bisulfite conversion efficiency 
30 million reads were randomly extracted from trimmed FASTQ sequence files 
and then mapped to the complete lambda genome (NCBI ID NC_001416.1) using 
Bsmap. Methylation signals were calculated with the Methratio.py in the Bsmap package 
(Xi & Li, 2009). To determine M.SsI efficiency, CpG sites on both forward and reverse 
strands were chosen and average methratio of these sites was calculated. CHH and CHG 
sites on both forward and reverse strands were chosen for the calculation of the bisulfite 
efficiency. Bisulfite efficiency was determined using the formula: 1- average methratio. 
Calling of 5fC/5caC bases 
5fC/5caC bases were called as described in Neri et al., 2015. Briefly, the number 
of C bases (C,5mC, 5hmC, referred to as NC) and T bases (5fC/5caC, referred to as NT) 
were determined. A binomial distribution pattern was used to determine the probability 
that NT occurred by chance (sequencing coverage (N) = NT + NC) ; p is error rate of 
methylation). 
Identifying Differentially Methylated Regions (DMRs) for 5fC/caC 
CpG sites on both forward and reverse strands were chosen for the DMR analysis 
using R package Bsseq (Hansen, n.d.). After computing t-statistics, we used cutoff=1, 
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which was determined based on the quantiles of the t-statistics (for the entire genome). 
DMRs that had <3CpG sites were excluded from further analysis. Moreover, we 
considered only DMRs (across the DMRs) with a mean difference in methylation 
between A2058 and Mel-Juso of at least 0.1. DMRs were intersected with promoter (+/- 
2k) and genebodies (hg19 Refseq) to determine target genes and perform Gene Ontology 
analysis. Heatmaps of DMRs were drawn with R package. 
Identifying Unique Differentially Methylated 5fC/caC sites (DMC) 
Only CpG sites that overlapped in all of the analyzed samples were called as 
uniquely and differentially methylated 5fC/5caC sites (DMC). We used different cutoffs 
(2,3,4) to filer the DMCs. These specific 5fC/caC sites were intersected with promoter 
(+/- 2k) and genebodies (hg19 Refseq) to determine target genes, which enables us to 
perform Gene Ontology analysis. Venn diagrams and heatmaps were drawn with R 
packages.  
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RESULTS 
Technique Validation 
 MAB-seq is a recently established technique that maps 5fC/5caC at single base 
pair resolution genome wide. The method is dependent on both successful enzymatic 
modification by M.SssI and chemical modification by bisulfite treatment. To establish a 
baseline for which to standardize the data for bioinformatic analysis, the efficiency of 
methylation and bisulfite conversion was determined. This was carried out by analyzing 
the unmethylated lamba DNA, which was spiked in prior to M.SssI treatment. The 
methylation efficiency for A2058 was 97.62% and bisulfite conversion was 96.96%. For 
Mel Juso, the methylation efficiency was 97.91% and the bisulfite conversion was 
97.45%. These values are consistent with those described in both Neri et al., 2015 and 
Wu et al., 2014 confirming the successfulness of this approach. 
5fC/5caC are Abundant Modifications in Melanoma 
Using MAB-seq, only two outcomes, C or T, are possible, therefore I used a 
binomial distribution pattern to quantitate the total number of 5fC/5caC sites genome 
wide. In A2058, 5fC/5caC sites comprise 3.37% of the total CpG sites, while in Mel Juso 
they comprises 4.28% (Figure 1A). The level of 5fC/5caC can be interpreted as the 
fraction of times a specific site is modified within that sample (Lister et al., 2009). The 
median level of modification in A2058 is 48.75%, while the levels in Mel Juso are on 
average 52.77% (Figure 1B and C).  
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Figure 1: Genome-wide levels of 5fC/5caC in melanoma cell lines. (A) The 
percentage of 5fC/5caC sites in the genome in respect to thetotal number of CpG sites in 
A2058 and Mel Juso. (B) Graphical representation of the levels of modification in 
A2058 and Mel Juso. (C) The number of 5fC/5caC sites corresponding to the levels of 
modification 
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5fC/5caC is Present in Regions Involved in Gene Expression 
To identify where these modifications are enriched within the genome, I first 
focused on regions that are implicated in gene expression. Analysis revealed that in both 
cell lines, 5fC/5caC is abundant within genes, promoter regions and to a lesser extent 
CpG islands. Within these regions, the levels of 5fC/caC remained constant according to 
cell line type and were present at approximately 40% in A2058 and 45-50% in Mel Juso 
(Figure 2).  
 
 
Figure 2: 5fC/5caC is an abundant modification in regions involved in gene 
expression. The graphs illustrate the percent of 5fC/5caC present in specific regions within 
the genome including CpG islands, gene coding regions and promoters in A2058 and Mel 
Juso.  
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To further examine the role these markings may have in gene expression, I 
studied the patterns of 5fC/ 5caC distribution across promoter regions and gene bodies of 
enriched genes. Both cell lines behave in a similar pattern, with Mel Juso containing 
higher levels of the modification. Across promoter regions, there is a drastic increase in 
the percentage of 5fC/5caC at transcription start sites. This level steadily declines as you 
move bidirectionally from this region (Figure 3A). The levels of 5fC/5caC remain fairly 
constant throughout gene bodies, however there is a small, but obvious, decrease at 
transcription end sites (Figure 3B). Collectively, these findings suggest that in genes 
enriched in this modification, there may be an overarching pattern for how 5fC/5caC is 
distributed across gene coding elements, which may translate into alterations of gene 
expression in melanoma.  
Figure 3: Distribution patterns of 5fC/5caC at transcription start sites and gene 
bodies. (A) Normalized levels of 5fC/5caC across  promoter regions (4k base pairs 
flanking the TSS) of genes enriched in these marks. (B) Normalized levels of 
5fC/5caC within gene bodies of genes eriched in these marks.  
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Distrubution of 5fC/5caC Throughout the Genome 
To better understand these regional distinctions, I examined the genome wide 
distribution of these modifications. Both A2058 and Mel Juso exhibited similar 
distributional patterns. Approximately half of the total 5fC/5caC sites were localized to 
intergenic regions. 40% of the remaining sites were present within intronic regions, while 
promoters and exons accounted for around 5% and 2%, respectfully (Figure 4). These 
findings are consistent with the literature, confirming the accuracy of the MAB-seq. 
Although the prevalence of 5fC/5caC varies between the cell lines, the overarching 
distributional patterns appear to be well matched.  
 
  
Figure 4: Overall genomic distribution of 5fC/5caC. In both cell lines, the 
distributional patterns of 5fC/5caC sites are similar. These modifications are most 
prevalent in distal intergenic regions, introns, promoters, and exons. 
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A2058 and Mel Juso Exhibit Differential Modification on a Regional Scale 
To see how the cell lines behave regionally, I narrowed in my focus to in order to 
identify regions with varying levels of modification. Differentially methylated regions 
(DMRs) take into consideration stretches of the genome, which contain more than one 
CpG site. For this comparison, only DMRs that were statistically significant (p<0.05) 
were chosen. When comparing A2058 to Mel Juso, there are 557 hypomethylated regions 
and 551 hypermethylated regions (Figure 5). Although the cell lines exhibit similar broad 
distributional patterns, they behave quite differently regionally. When taken together, 
these findings bring to light that the heterogeneosity that is characteristic of malignant 
melanoma is also present within representative cell lines 
 
 
 Using the 5fC/5caC regions identified through DMR analysis, I set out to 
determine the functionality of these genes. To help narrow down the regions, I focused 
the analysis on the 551 hypermethylated regions, in respect to A2058. Using the Gene 
Figure 5: Differentially methylated regions (DMRs) between A2058 and Mel Juso. 
Differentially methylated regions take into account stretches of the genome with more 
than one CpG site. When comparing A2058 to Mel Juso, there are 557 hypomethylated 
regions and 551 hypermethylated regions. The methylation score corresponds to the 
levels of 5fC/5caC in that region, where 500 is the lowest level of modification and 2000 
is the highest level of modification.  
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Functional Classification Tool on DAVID Bionformatics Resources, I was able to group 
the genes according to the functionality of their proteins, only including the ones reaching 
statistical significance (p<0.001) (Huang, Sherman, & Lempicki, 2008, 2009). Genes 
identified within hypermethylated regions of A2058 are involved in processes related to 
cell growth and proliferation, including adhesion, metabolism, and transcription (Figure 
6). Uncharacteristically, many genes within this region are also involved in neuronal 
development and differentiation. 
 
 
Deregulation of cell signaling pathways is a major factor in the development and 
progression of melanoma (reviewed by Paluncic et al., 2016). To understand how 
Figure 6: Gene ontology for genes identified within hypermethylated DMRs of 
A2058. The genes chosen for this analysis were identified using the hypermethylated 
DMRs in A2058 in respect to Mel Juso. Genes were classified into groups based on the 
functionality of their proteins. Functional classifications were chosen based on statistical 
significance (p<0.001). 
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5fC/5caC enrichment in melanoma cell lines may impact these pathways, I used DAVID 
Bionformatics Resources to identify KEGG pathways for the A2058 hypermethylated 
regions identified from the DMRs. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analysis integrates whole genome data-sets with known molecular networks to create a 
comprehensive map of the components, pathways and functions, which are implicated in 
a variety of cell processes and diseases. As with gene ontology, the genes chosen for this 
analysis were identified using hypermethylated DMRs corresponding to A2058, and only 
pathways of statistical significance ( p<0.05) were taken into consideration. Analysis 
revealed that genes within these 5fC/5caC regions correspond to those involved in cancer 
and cell signaling. Consistent with the gene ontology, pathways implicated with neuronal 
processes were also identified (Figure 7). 
 
Figure 7:5fC/5caC enriched regions in A2058 correspond to various KEGG 
pathways. The genes chosen for this analysis were identified using the 
hypermethylated DMRs in A2058 in respect to Mel Juso. Only pathways of 
statistical significance (p<0.05) were chosen. 
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A2058 and Mel Juso are Differentially Modified at Base Pair Resolution 
To see whether A2058 and Mel Juso are differentially modified at base pair 
resolution, I examined where these sites occur. A comparison of the cell lines revealed 
that 316258 sites overlapped between them (Figure 8A). I next examined the levels of 
5fC/5caC at these overlapping sites. To help narrow down potential sites of interest, I 
filtered the differentially methylated CpGs (DMCs) with a cut off of 3. This means that 
sites within a cell line are only considered if they contain levels of 5fC/5caC that are  ≥3 
times higher in respect to the other cell line. Using this cut off, 23036 differentially 
methylated sites were identified, 9991 specific to A2058 and 13045 specific to Mel Juso 
(Appendix Figure 1). To help narrow down these sites, I applied a stricter cutoff of 4, 
meaning that only sites with a ≥4 fold change are considered. This cutoff reduced the 
total number DMCs to 8860, with 3773 of the sites being specific to A2058 and 5087 
sites being specific to Mel Juso (Figure 8B).
 
Figure 8: Examining 5fC/5caC at base pair resolution. (A) Venn diagram showing the total 
number of 5fC/5caC sites in each cell line. (B) Heatmap comparing the differentially 
methylated CpG sites (DMCs) that are in common between A2058 and Mel Juso. Overlapping 
sites were filtered with a cut off of 4, meaning only sites with ≥4 fold change in the levels of 
5fC/5caC are considered. 3773 sites are A2058 specific and 5087 are Mel Juso specific. 
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To further investigate the importance of these regions, I used KEGG analysis to 
map 5fC/5caC genes associated with differentially sites for pathways that are disrupted in 
cancer. KEGG analysis revealed that in both cell lines, many of the genes coding for cell 
signaling components are enriched in 5fC/5caC. All of the major cell signaling pathways, 
including Wnt, MAPK, MTOR, VEGF, P53, PPAR and JAK-STAT, were shown to have 
enriched components, which could potentially translate to excess stimulation. Alterations 
in these pathways disturb critical cell processes, resulting in the ability to abnormally 
proliferate, invade tissues/metastasize and avoid apoptosis (Figure 9A and B). KEGG 
enrichment analysis also revealed that the melanogenesis pathway was of significance in 
A2058. 14 of the 39 potential targets are enriched for 5fC/5caC in this cell line, 
suggesting the deregulation of this pathway may be of increased importance in the later 
stages of the melanoma (Figure 10). Collectively, these results show that genes involved 
in deregulated cell signaling pathways may be marked by 5fC/5caC. 
To better understand the how differentially methylated CpG sites may contribute 
to melanoma progression, I examined the genes that correlated with these sites. I chose 
20 genes from each cell line with maximal differences in the levels of 5fC/5caC between 
them. In other words, I examined the genes where the levels of A2058 were 100 and the 
levels of Mel Juso were low, and vice versa. Using the NCBI gene database, I examined 
the functions of these encoded proteins (Appendix Table 1). For both cell lines, many of 
these enriched genes encoded for components involved in cell signaling and cell 
growth/proliferation. These findings are consistent with the results from KEGG analyses, 
indicating that 5fC/5caC enriched genes may have a role in the deregulation of cell 
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signaling pathways. Moreover, a few of the genes of the genes identified in A2058 
correspond with proteins involved in neuronal processes, which is consistent with my 
findings from both gene ontology and KEGG. 
To see if there may be an interplay between the genetic and epigenetic 
components involved in familial melanoma and 5fC/5caC, I examined the 8 genes (cell 
cycle associated: CDKN2A, CDK4, BAP1 and MITF; telomerase function: TERT ACD, 
POT1 and TERF2IP) which are implicated in familial cases at base pair resolution 
(Figure 11). When comparing the cell lines, there are clear changes in the number, 
location and levels of 5fC/5caCsites within these regions. This further supports the notion 
that both cell lines exhibit differences at base pair resolution, and also suggests that 
5fC/5caC may have a role in the expression of genes associated with familial melanoma. 
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 Figure 9A: 5fC/5caC enriched cancer pathways in A2058. KEGG pathway analysis revealed that 
5fC/5caC enriched genes in A2058 correspond to components of cell signaling pathways that are deregulated 
in cancer. A red star indicates enriched components. 
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Figure 8B: 5fC/5caC enriched cancer pathways in Mel Juso. KEGG analysis revealed that 5fC/5caC enriched genes 
in Mel Juso correspond to components of cell signaling pathways that are deregulated in cancer. A red star indicates 
enriched components. 
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Figure 10: The melanogenesis pathway in A2058. KEGG analysis highlighted that in the A2058 
cell line, genes coding for components involved in melanogenesis are enriched in 5fC/5caC. A red 
star indicates enriched components. 
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Figure 11: Base pair resolution of genes implicated in familial melanoma. Examination of genes involved in 
familial melanoma at base pair resolution revealed differential methylation patterns between A2058 and Mel Juso. 
5fC/5caC varies in the number and location of sites, along with the level of modification. Red boxes indicate a few 
regions where these differences are observed. (A) Genes involved in cell cycle regulation: CDKN2A, CDK4, BAP1 
and MITF. (B) Genes involved in telomerase function: TERT, ACD, POT1 and TERF21P.  
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DISCUSSION 
As the prevalence of melanoma continues to rise, understanding the role 
epigenetics plays in this oncogenic transformation becomes more crucial. Using MAB-
seq, I have mapped the level and whole genome distribution of 5fC/5caC at base pair 
resolution in two melanoma cell lines, A2058 and Mel Juso. By mapping this 
modification on a whole genome scale, I was able to determine the total number of 
5fC/5caC sites and their distribution throughout the genome. The levels of 5fC/5caC are 
elevated in regions involving gene expression, especially the transcription start sites of 
enriched genes. Comparisons between the cell lines revealed differentially methylated 
sites and regions, with many of the enriched genes corresponding to cell processes such 
as growth, differentiation and cancer signaling pathways. This study is, to our knowledge, 
the first to explore 5fC/5caC in a disease model and reveals that these modifications may 
indeed have a role in the development and progression of melanoma, warranting further 
investigation in patient samples. 
Mel Juso contained both more sites and higher levels of 5fC/5caC as compared to 
A2058. The levels of TET protein in each of the cell lines could, potentially, explain this 
observation. A study evaluating TET protein expression in various malignant melanoma 
cell lines demonstrated that cell lines corresponding to metastatic melanoma, including 
A2058, had lower levels of TET when compared to cell lines associated with only 
vertical or radial growth (Gustafson et al., 2015). Lower levels of TET expression in 
A2058 would result in less oxidation of 5mC and 5hmC, therefore reducing the 5fC/5caC 
content. 
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Genes enriched for 5fC/5caC in melanoma cell lines show elevated levels of these 
modifications at promoter regions, especially those flanking transcriptional start sites. 
This finding is consistent with what has been observed using both base pair resolution 
and affinity enrichment techniques. In mESCs, increased levels of 5fC/5caC correspond 
to regions marked with H3K4me1 and H3K4me3, which are histone marks associated 
with enhancer regions or active promoters (Neri et al., 2015; Shen et al., 2013; Song et al. 
2013; Wu et al., 2014). The initial paper which presented this concept was antibody-
based method reported that within the promoter regions, these markings correlate with 
poised or repressed promoters (Shen et al., 2013). More recent and refined studies have 
shown that promoters marked by 5fC/5caC are associated with active promoters, 
indicative of gene expression (Neri et al., 2015; Wu et al., 2014).The presence of 
5fC/5caC within promoter regions in these melanoma cell lines may, therefore, also be 
indicative of active promoter regions.  
To support the concept that 5fC/5caC is associated with regions of active gene 
expression, it has also been shown that DNAse hypersensitive sites are enriched in 
5fC/5caC. Moreover, enhancers marked by H3K27Ac or H3K4me1, which are marks 
corresponding to active genomic regions, are also enriched in 5fC/5caC (Neri et al., 2015; 
Shen et al., 2013; Song et al. 2013; Wu et al., 2014).Thus, the elevated levels of 
5fC/5caC that I observed within distal intergenic regions may correspond to regulatory 
elements such as active enhancers, which are involved in promoting gene expression. It 
must also be taken into consideration that these studies have used mESC as their 
experimental model. To further support that 5fC/5caC is a mark of gene activation in a 
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melanoma disease model, transcriptome data and concurrent histone markings are 
required. 
In melanoma, it has been shown that the loss of 5hmC occurs primarily within 
intergenic regions (Lian et al., 2012). Consistent with this, 5fC/5caC is primarily 
localized within intergenic regions. It has been shown there is an inverse relationship 
between 5hmC and 5fC/5caC, where 5fC/5caC is more abundant in regions that are 
depleted of 5hmC (Shen et al., 2013; Song et al. 2013). This, therefore, suggests a 
possible shift in the oxidation dynamics of TET proteins. Although elevated levels of 
5fC/5caC have been noted in intragenic regions, much less is known about their function. 
It is, however, speculated that they influence gene transcription (Neri et al., 2015; Shen et 
al., 2013; Song et al. 2013; Wu et al., 2014). It has recently been shown that within these 
regions, 5fC/5caC alters the kinetics of RNA Polymerase II, resulting in a slower 
transcriptional process. The reasoning for this is not well understood, however the delay 
introduced by these modifications may act as a signal for TDG or chromatin remodeling 
complexes (Wang et al., 2015). It would be of interest to note if there is overlapping loss 
of 5hmC and gain of 5fC/5caC at specific sites/regions, which would help us further 
understand the aberrant DNA demethylation in melanoma.  
Because 5fC/5caC is a potential mark of gene activation depending on genome 
localization, it is important to recognize where theses marks occur in melanoma in order 
to understand their potential contribution to disease progression. Comparisons between 
A2058 and Mel Juso revealed that there is a small number of overlapping 5fC/5caC sites 
between the cell lines and that many of these sites exhibit varying levels of modification. 
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This differential methylation is also present when comparing regions accounting for 
multiple CpG sites. Understanding the patterns of modification and which genomic 
elements they correspond to are important when deciphering the role of epigenetics 
underlying melanoma progression. Identifying overlapping sites/regions, which contain 
similarly elevated levels of 5fC/5caC within these cell lines, provides a basis for 
identifying specific elements that may be requisite for melanoma. Conversely, identifying 
sites/regions that are differentially methylated could expose elements that become 
modified with melanoma progression and metastasis. Examining these regions more 
closely and applying them to patient samples will help us better comprehend how 
differentially methylated sites/regions correlate with disease progression and melanoma 
development.  
Looking more specifically at the gene ontology and KEGG pathways 
corresponding to hypermethylated DMR regions in A2058, the functionalities and 
pathways highlighted go hand in hand with processes required for tumor growth and 
metastasis. Alterations in cell adhesion patterns are a requirement for tumor formation 
and migration in melanoma. Throughout oncogenic transformation, melanocytes, 
characteristically, “switch” their cadherin expression, from E- cadherin to N-cadherin. 
This downregulation of E-cadherin and subsequent up-regulation of N-cadherin alters the 
preference of melanocytic adhesion from kerotinocytes to vascular endothelial cells, 
which contributes to tumor formation and migration (Wheelock, Shintani, Maeda, 
Fukumoto, & Johnson, 2008). Furthermore, there is generalized up-regulation of various 
other adhesion molecules, which also contribute to tumor growth and progression (Haass, 
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Smalley, Li, & Herlyn, 2005). It may be the case that enrichment of 5fC/5caC promotes 
the expression of these cell adhesion molecules, contributing to the pathogenesis of 
melanoma. The involvement of genes involved in metabolism, regulation of transcription 
and nucleotide/nucleobases would also be consistent with the processes required to fuel 
proliferation of melanocytes. 
The other major functional classes identified through gene ontology involved 
neuronal-specific processes. Although initially puzzling, this may be a result of cell 
origin. From an embryologic standpoint, melanocytes are derived from neural crest cells 
(Ivanov & Hei, 2015). These neural crest cells also give rise to neuronal precursors, 
which further develop into the specialized cells of the nervous system (Gilbert, 2000). In 
terms of pathology, as tumor cells become more malignant, they exhibit increasing 
degrees of anaplasia, approaching a dedifferentiated state, where they resemble their 
progenitor cells (Lee, Murphy, & Lian, 2014). In other words, it may be possible that as 
melanoma becomes more malignant, as the case with metastatic A2058, the cells begin to 
dedifferentiate and, as a result of 5fC/5caC enriched genes, display default neuronal 
markers. In support of this, it has been shown that melanoma can express neuronal-
related biomarkers, including nestin, inhibitor of DNA 4 and Brn3a (Hohenauer et al., 
2013; Ivanov & Hei, 2015; Peretz, Wu, Patel, Bellacosa, & Katz, 2015). Furthermore, 
melanocytic tumors with neural components have been observed clinically and are 
referred to as desmoplastic neurotropic melanoma (Anstey, Mckee, & Jones, 1993; 
Kossard S, Doherty E, & Murray E, 1987; Su et al., 2014). The presence of long term 
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depression as a result of KEGG analysis is also consistent with the idea of the activation 
of neural associated genes. 
Mapping of enriched genes identified from DMCs using KEGG analysis 
highlighted that many cancer pathway components are enriched in 5fC/5caC. One of the 
most critical pathways in these cell lines is the MAPK/ERK pathway. Briefly, binding of 
epidermal growth factors to their membrane receptors activates tyrosine kinases, which 
activate RAS. RAS then triggers a signaling cascade, through which RAF and MEK1/2 
become active. This contributes to the activation of ERK, which is involved in the 
regulation of growth related transcription factors. ERK activation triggers expression of 
these transcription factors, resulting in increased proliferation. Over activation of the 
major constituents of this pathway, possibly resulting from 5fC/5caC enriched gene 
transcription, leads to uncontrolled cell growth (Johnson, Stuhlmiller, Angus, 
Zawistowski, & Graves, 2014). The MAP/ERK pathway is also involved in stimulating 
another major signaling pathway, PI3K/AKT, which is involved in cell growth, 
proliferation, and survival. In this pathway, PI3K phosphorylates AKT, which inhibits 
GSK3. This inhibition allows for the accumulation of beta-catenin in the cytoplasm, 
which can then migrate to the nucleus and induce expression of growth-related 
transcription factors. In melanoma, excess beta-catenin accumulates in the cytoplasm, 
leading to an up regulation of these growth-promoting factors. The Wnt signaling 
pathway functions in a similar manner, relying on the accumulation of beta-catenin to 
induce transcription (Paluncic et al., 2016). In normal cells, the Transforming Growth 
Factor Beta (TFG-) pathway acts to inhibit growth through the induction of CDK 
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inhibitors, promotion of apoptosis genes and repression of growth factors. Cells within 
melanocytic lesions, however, produce excess TFG-, allowing the cell to confer TFG- 
resistance, which results in cell growth. In more advanced stages of the disease, 
deregulation of this pathway promotes epidermal to mesenchymal transition, which is a 
requirement for metastasis (Perrot, Javelaud, & Mauviel, 2013). Collectively, the cell 
signaling pathways mentioned here are extremely complex, intertwining webs which, 
when deregulated, can result in oncogenesis. The potential role of 5fC/5caC in gene 
activation and expression may result in over activation/stimulation of cell signaling 
pathways, ultimately contributing to neoplastic growth.  
Melanin is one the skin’s primary protective mechanisms against UV damage. 
Melanin is synthesized by melanocytes within specialized vesicles called melanosomes, 
which are then released into keratinocytes. This process, termed melanogenesis, is under 
strict control by various cell signaling pathways (Costin & Hearing, 2007). My KEGG 
analysis revealed that in A2058, various components of the melanogenesis pathway are 
enriched in 5fC/5caC. Briefly, this pathway is triggered by the binding of melanocyte-
stimulating hormone and adrenocorticotropic hormone to their respective receptors, 
which activates adenylate cyclase. Cyclic AMP triggers a phosphorylation cascade, 
which results in the increase of MITF expression. MIFT is responsible for inducing the 
transcription of enzymes responsible for melanin production, along with factors that 
promote cell proliferation and survivability (Costin & Hearing, 2007; Wellbrock & 
Arozarena, 2015). Wnt and MAPK signaling pathways also stimulate the melanogenesis 
pathway, resulting in increased MIFT expression. Enrichment of 5fC/5caC in genes 
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encoding for melanogenesis signaling components may translate to over expression of 
these elements. This would, consequentially, over stimulate the melanogensis the 
pathway, resulting in increased melanin production along with increased cell proliferation 
and survivability. 
The genes identified using DMCs, highlighted critical components involved in 
fueling melanoma. In A2058, 5fC/caC marked genes coded for proteins involved in cell 
signaling, including GTPases (RAB11FIP4 and RHEB), components of Wnt and MAPK 
signaling (RNF220 and KSR2) and transcriptional activators/ repressors (SPIN and 
GIGYF1) (Franz et al., 2015; Horgan, Hanscom, Kelly, & McCaffrey, 2012; Karassek et 
al., 2010; Liu et al., 2009; Ma et al., 2014; Morita et al., 2012). Consistent with the results 
from gene ontology, many of the enriched genes correspond to those involved in neuronal 
processes. These include neuron-specific RNA splicing (RBFOX3), neuronal 
proliferation and migration (DISC1) and neuronal organization (DAB1) (Greenhill et al., 
2015; Lucas, Calvez, Babu, & Brown, 2014; Rice et al., 1998). Although just in the 
beginning stages, these findings give us a glimpse of how 5fC/5caC might be involved in 
expressing genes, which contribute to the dedifferentiation of oncogenic melanocytes 
through facilitating of the expression of neuronal markers. 
In Mel Juso, majority of the genes identified from DMCs corresponded to 
proteins involved in cell signaling pathways that result in cell proliferation. For example 
PRKCZ, VAV3, NRG3 and INPP5B all code for elements involved in signal transduction 
pathways, including MAPK, phosphatidylinositol pathway and epidermal growth factor 
receptor signaling (Carteron, Ferrer-Montiel, & Cabedo, 2006; Cornford et al., 1999; 
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Williams, Choudhury, McKenzie, & Lowe, 2007; Zugaza et al., 2002). There were also a 
few genes, most notably pre B cell leukemia homeobox 1(PBX1) and paired related 
homeobox 1 (PRRX1), which are associated with enhanced gene transcription (Guo et 
al., 2015; Magnani, Ballantyne, Zhang, & Lupien, 2011). Ongoing, active transcription of 
these 5fC/5caC marked genes, would fit hand-in-hand with the over stimulation of 
signaling pathways that contributes in promoting melanoma growth. 
Melanoma cases classifying as familial or genetically inherited are restricted to 
mutations in a small set of genes. To see whether 5fC/5caC may be implicated in these 
genes as well, I examined these regions at base pair resolution. 5fC/5caC is abundant in 
these regions, with cell type specific variation in the location, number of sites, and levels 
of modification. The presence of 5fC/5caC within these regions indicates the intertwining 
relationship between genetic and epigenetic factors in melanoma, however further 
analysis is required to determine the potential role of these marks in regulating melanoma 
associated genes. 
In summary, this study has shown that 5fC/5caC is a prominent mark in this 
melanoma cell line disease model. Although it’s genomic distribution pattern remains 
consistent, only a small fraction of 5fC/5caC sites overlap between the cell lines, and may 
represent sites that are specific to the development and progression of melanoma. In 
addition, many of the genes that are enriched for this mark correspond to those involved 
in cancer promoting pathways. The results obtained from these studies have shown to be 
promising, and merit further and more in depth exploration. 
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Using the knowledge gained from this study as a foundation, we will expand this 
project in various directions. First and foremost, we will incorporate two malignant 
melanoma and two benign nevi samples into the experimental design. I have already 
performed MAB-seq on these samples, which have been sequenced and are currently 
undergoing analysis. Inclusion of these samples this will provide a more comprehensive 
disease model, with the nevi samples serving as our “normal” baseline/negative control. 
It will be of interest to note how these patient samples behave when compared to the cell 
lines and benign nevi in regards to the number of sites, percent of modification, genomic 
distribution and specific signatures of 5fC/5caC. It will be noteworthy to see if the 
overlapping sites identified between these cell lines are also present within the patient 
melanoma samples. With the incorporation of RNA-seq data, we plan to delve deeper in 
order to validate the role of 5fC/5caC on gene transcription and to identify distinct 
regions that are altered in the progression from benign nevi to malignant melanoma. 
Because the criteria for melanoma diagnosis are tremendously subjective, 
identification of these distinct regions and how they change throughout disease 
progression could serve as diagnostic and prognostic biomarkers. Furthermore, 
characterizing the involvement of 5fC/5caC enriched gene products in cell-signaling 
pathways may identify new targets for pharmaceuticals used in the treatment of 
metastatic melanoma. Through this project, we aim to contribute novel insight to the field 
of epigenetics and melanoma, which can be applied to better characterize, diagnose and 
treat this disease.   
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APPENDIX 
Appendix Figure 1 
 
  
Appendix Figure 1: Examining 5fC/5caC at base pair resolution. (A) Venn diagram 
showing the total number of 5fC/5caC sites in each cell line. (B) Heatmap comparing the 
differentially methylated CpG sites (DMCs) that are in common between A2058 and Mel 
Juso. Overlapping sites were filtered with a cut off of 3, meaning only sites with ≥3 fold 
change in the levels of 5fC/5caC are considered. Out of the 23036 differentially methylated 
sites, 9991 are A2058 specific and 13045 are Mel Juso specific. 
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Appendix Table 1 
 
Level of 
5fC/5caC 
in 
A2058 
Level of 
5fC/5caC 
in Mel 
Juso 
Gene Name Protein function Reference 
100 7.4 RBFOX3 
 
Neuron specific RNA splicing 
factor 
 
(Lucas, Calvez, 
Babu, & Brown, 
2014) 
100 9.4 
 
KSR2 
 
Scaffold protein in MAPK 
signaling 
 
(Liu et al., 2009) 
 
100 9.4 
 
GRB10 
 
Adaptor protein that interacts 
with tyrosine kinase receptors 
(Morrione, 2003) 
100 11.1 
 
MTMR10 
 
Protein involved in the 
phosphatidylinositol signaling 
pathway 
(Wishart & Dixon, 
2002) 
 
100 11.1 
 
GIGYF1 
 
Interacts with another protein to 
form a translational repressor 
complex 
(Morita et al., 
2012) 
 
100 11.4 
 
RAB3C 
 
GTPase in the RAS family (Cheng et al., 
2002) 
100 11.8 
 
TACC2 
 
Protein invovled in cell cycle 
regulation 
(Takayama et al., 
2012) 
100 12.0 
 
HNRNPUL2 
 
Protein invovled in double 
stranded DNA break repair 
signaling 
(Polo et al., 2012) 
 
100 12.2 
 
FUT8 
 
Glycosyltransferase that has been 
associated with prostate cancer 
(Wang et al., 
2014) 
100 12.8 
 
RAB11FIP4 
 
GTPase involved in intracellular 
trafficking 
 
(Horgan, 
Hanscom, Kelly, 
& McCaffrey, 
2012) 
100 13.0 
 
KALRN 
 
Guanine nucleotide exchange 
factor that is crucial in neuronal 
spine placisity 
(Mandela & Ma, 
2012)(Penzes & 
Remmers, 2012) 
100 13.2 
 
DISC1 
 
Protein invovled in neuronal 
development processes such as 
proliferation and migration 
(Greenhill et al., 
2015) 
 
100 13.2 
 
RHEB 
 
GTPase that is enriched in the 
brain and invovled in cell growth 
(Karassek et al., 
2010) 
Table 1: 5fC/5caC enriched genes identified using DMCs. To better understand the role 
of 5fC/5caC in the melanoma cell lines, DMCs were used to identify genes which are 
differentially enriched in 5fC/5caC. 20 genes with maximal levels of 5fC/5caC were chosen 
from each cell line. Full gene names can be found within the abbreviation list section. 
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and proliferation 
 
 
100 13.3 
 
NELL1 
 
Protein with an ability to induce 
bone formation 
(Shen et al., 2015) 
100 14.9 
 
RNF38 
 
Ubiquitin ligase that interacts 
with p53 
 
(Sheren & 
Kassenbrock, 
2013) 
100 14.9 
 
INPP1 
 
Phosphatase involved in the 
phosphatidylinositol signaling 
pathway 
(York, Veile, 
Donis-Keller, & 
Majerus, 1993) 
100 15.2 
 
DGKB 
 
Diglyceride kinase beta, which is 
involved in DAC signaling 
(Caricasole et al., 
2002) 
100 15.6 
 
SPIN1 
 
Histone code reader associated 
with cell proliferation 
(Franz et al., 
2015) 
100 18.6 
 
RNF220 
 
Complexes with USP7 to 
deubiquitinate β-catenin, 
enhancing Wnt signaling 
(Ma et al., 2014) 
 
100 18.8 
 
DAB1 
 
Protein involved in the signaling 
pathway leading to neuronal 
organization in the developing 
brain 
(Rice et al., 1998) 
 
11.6 
 
100 FAM5C 
 
Protein of unclassified function 
but found to induce growth in 
pituitary adenomas 
(Shorts-Cary et 
al., 2007) 
 
12.2 
 
100 PBX1 
 
Homeodomain containing protein 
that associates with HOX and is 
implicated in various cancers 
 
(Magnani, 
Ballantyne, 
Zhang, & Lupien, 
2011) 
13.2 
 
100 PRRX1 
 
Homeobox protein that has been 
shown to activate Wnt signaling 
(Guo et al., 2015) 
 
13.3 
 
100 RGS7 
 
 
GTPase accelerating protein 
 
(Masuho, Xie, & 
Martemyanov, 
2013) 
13.8 
 
100 SDCCAG8 
 
Centrosome associated protein 
 
(Kenedy, Cohen, 
Loveys, Kato, & 
Dang, 2003) 
14.3 
 
100 HHAT 
 
Hedgehod acyltransferase 
 
(Matevossian & 
Resh, 2015) 
14.8 
 
100 PDE4B 
 
Subunit of a cAMP-specific 
phosphodiesterase 
(Houslay & 
Adams, 2003) 
15.2 
 
100 PRKCZ 
 
Isoform of protein kinase C 
(PKC) 
(Cornford et al., 
1999) 
15.6 
 
100 NUP133 
 
Nucleoporin 
 
(Boehmer, Jeudy, 
Berke, & 
Schwartz, 2008) 
15.8 
 
100 KAZ 
 
Protein involved in desmosome 
regulation, epidermal 
(Nachat et al., 
2009) 
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differentiation, and embryonic 
development 
 
15.8 
 
100 NRG3 
 
Ligand for epidermal growth 
factor receptor family 
 
(Carteron, Ferrer-
Montiel, & 
Cabedo, 2006) 
17.1 
 
100 GNG12 
 
G protein subunit gamma 12 (Cook et al., 2001) 
17.4 
 
100 DUSP10 
 
MAPK phosphatase (Tao & Tong, 
2007) 
17.4 
 
100 VAV3 
 
Guanine nucleotide exchange 
factor for Rho family proteins 
(Zugaza et al., 
2002) 
17.6 
 
100 INPP5B 
 
Inositol polyphosphate-5-
phosphatase 
 
(Williams, 
Choudhury, 
McKenzie, & 
Lowe, 2007) 
18.2 
 
100 CAMTA1 
 
Calmodulin-binding transcription 
activator 
(Schraivogel et al., 
2011) 
18.2 
 
100 TRIM45 
 
Transcriptional repressor in 
MAPK pathway 
(Wang et al., 
2004) 
18.5 
 
100 SMYD3 
 
Histone methyltransferase (Eberle et al., 
2014) 
20 
 
100 RASSF5 
 
Member of the Ras association 
domain family and is a putative 
tumor suppressor 
(Guo et al., 2015) 
 
20 
 
100 RABGAP1L 
 
RAB GTPase 
 
(Roberti et al., 
2009) 
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